U.S. Patent No. 12,780,831 covers posiphen (buntanetap) D-tartrate Form B, a highly crystalline dihydrate, together with pharmaceutical compositions and methods of preparation, providing protection through 2044Form B is used in the Company’s ongoing pivotal Phase 3 trial in early Alzheimer’s disease and in the open-label extension Parkinson’s studyIssued patent strengthens the Company’s intellectual property position ahead of the top-line data readout from its fully enrolled pivotal Phase 3 Alzheimer’s tria ...